New Axiron Roll-on for treating Low Testosterone

Though testosterone levels plummeting with age is a normal occurrence in males, but low testosterone could have an effect on their health. In a myriad ways, testosterone is the stuff making men what they are. All through a man’s lifetime, testosterone is known to maintain a man’s characteristics and plummeting progressively subsequent to crossing forty years of age. The drop is comparatively diminutive, averaging nearly one to two percent annually. On reaching mid-age and over, practically all males experience dip in testosterone, however only a miniscule proportion of aging males have testosterone levels far lower than deemed normal as per their age.

Low testosterone is referred to below three hundred nanograms/decilitre of blood reading. The signs of low testosterone comprise of low libido, erectile dysfunction, moodiness, lethargy, weariness and wakefulness. From all males with under normal testosterone levels, nearly a half or 2/3rd of them cites symptoms.

Andropause in males is an eventual plummet in testosterone levels over periods of time and even goes unseen. Several males having low testosterone levels are symptomatic without knowing them.

Quality of life in symptomatic males having low testosterone levels could be majorly impaired. Present medical opinion is that such males must undergo testosterone replacement treatment.

Replacement of low testosterone has been daily usage of skin gels, patch to be affixed to the skin, oral intake disintegrating pills or shots. The obtainable over-the-counter treatment for low testosterone is the topical application of a gel over the upper body of males which requires nearly ten minutes in drying up. The broad advice is raising the blood testosterone levels solely into standard range.

A novel roll-on with testosterone lacing that could bring about improvement in dwindling sex drive in males with low testosterone has been unveiled in the market. The roll-on, Axiron which is manufactured by Melbourne-based pharmaceutical company Acrux intended for once-a-day application has been snapped by pharmaceutical heavy weight, Eli Lilly for a sheer 335 million dollar deal.

Eli Lilly would have the marketing rights for the roll-on in nearly143 countries, once it gets the U.S. FDA (Food and Drug Authority) approval.

This deal is believed to be among the biggest permitting deals which have been embarked on by an Australia-based company.

Acrux has approximated that nearly thirty-nine percent of males past the age of fifty ail from low testosterone.

Acrux deems the worldwide market for Axiron is over one billion dollars and increasing at twenty percent yearly.